ADMA Biologics, Inc.

NasdaqGM:ADMA Stok Raporu

Piyasa değeri: US$4.5b

ADMA Biologics Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 2/6

ADMA Biologics has been growing earnings at an average annual rate of 19.1%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 49.8% per year. ADMA Biologics's return on equity is 18.5%, and it has net margins of 10.5%.

Anahtar bilgiler

19.1%

Kazanç büyüme oranı

43.2%

EPS büyüme oranı

Biotechs Sektör Büyümesi17.0%
Gelir büyüme oranı49.8%
Özkaynak getirisi18.5%
Net Marj10.5%
Sonraki Kazanç Güncellemesi07 Nov 2024

Yakın geçmiş performans güncellemeleri

ADMA Biologics' (NASDAQ:ADMA) Strong Earnings Are Of Good Quality

Aug 16
ADMA Biologics' (NASDAQ:ADMA) Strong Earnings Are Of Good Quality

Recent updates

ADMA Biologics, Inc.'s (NASDAQ:ADMA) 27% Price Boost Is Out Of Tune With Revenues

Oct 09
ADMA Biologics, Inc.'s (NASDAQ:ADMA) 27% Price Boost Is Out Of Tune With Revenues

ADMA Biologics: Riding High On ASCENIV's Success

Oct 02

ADMA Biologics, Inc.'s (NASDAQ:ADMA) Intrinsic Value Is Potentially 57% Above Its Share Price

Sep 06
ADMA Biologics, Inc.'s (NASDAQ:ADMA) Intrinsic Value Is Potentially 57% Above Its Share Price

ADMA Biologics' (NASDAQ:ADMA) Strong Earnings Are Of Good Quality

Aug 16
ADMA Biologics' (NASDAQ:ADMA) Strong Earnings Are Of Good Quality

ADMA Biologics: A Compelling GARP Stock For Biotech Investors

Jul 27

ADMA Biologics, Inc. (NASDAQ:ADMA) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

Jul 24
ADMA Biologics, Inc. (NASDAQ:ADMA) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

Is ADMA Biologics (NASDAQ:ADMA) Using Too Much Debt?

Jul 17
Is ADMA Biologics (NASDAQ:ADMA) Using Too Much Debt?

Is ADMA Biologics, Inc. (NASDAQ:ADMA) Trading At A 43% Discount?

May 30
Is ADMA Biologics, Inc. (NASDAQ:ADMA) Trading At A 43% Discount?

ADMA Biologics, Inc. Just Beat EPS By 45%: Here's What Analysts Think Will Happen Next

May 13
ADMA Biologics, Inc. Just Beat EPS By 45%: Here's What Analysts Think Will Happen Next

Giving ADMA Biologics A Well-Deserved 'Booyah'

May 12

ADMA Biologics, Inc.'s (NASDAQ:ADMA) Prospects Need A Boost To Lift Shares

May 08
ADMA Biologics, Inc.'s (NASDAQ:ADMA) Prospects Need A Boost To Lift Shares

Is ADMA Biologics (NASDAQ:ADMA) A Risky Investment?

Apr 04
Is ADMA Biologics (NASDAQ:ADMA) A Risky Investment?

Rising Margins And Product Promise Drive ADMA Biologics Forward (Rating Upgrade)

Apr 03

ADMA Biologics: On A Roll Entering 2024

Jan 19

Is There An Opportunity With ADMA Biologics, Inc.'s (NASDAQ:ADMA) 50% Undervaluation?

Jan 09
Is There An Opportunity With ADMA Biologics, Inc.'s (NASDAQ:ADMA) 50% Undervaluation?

ADMA Biologics, Inc. (NASDAQ:ADMA) Surges 30% Yet Its Low P/S Is No Reason For Excitement

Jan 09
ADMA Biologics, Inc. (NASDAQ:ADMA) Surges 30% Yet Its Low P/S Is No Reason For Excitement

We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt

Oct 25
We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt

We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt

Jun 10
We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt

The Market Doesn't Like What It Sees From ADMA Biologics, Inc.'s (NASDAQ:ADMA) Revenues Yet

May 12
The Market Doesn't Like What It Sees From ADMA Biologics, Inc.'s (NASDAQ:ADMA) Revenues Yet

ADMA Biologics: Strong Growth Is Clearing The Path To Profitability

Aug 21

ADMA Biologics GAAP EPS of -$0.07, revenue of $33.9M

Aug 10

ADMA Biologics (NASDAQ:ADMA) Is Carrying A Fair Bit Of Debt

Jun 01
ADMA Biologics (NASDAQ:ADMA) Is Carrying A Fair Bit Of Debt

ADMA Biologics: A Path To Profits Looks Clear

May 12

ADMA: Pertinent Updates

Apr 18

ADMA Biologics' 2021 Numbers Showed Continued Strong Execution

Mar 29

ADMA Biologics: 2021 Was Tough

Jan 18

Gelir ve Gider Dağılımı

ADMA Biologics nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

NasdaqGM:ADMA Gelir, gider ve kazançlar (USD Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
30 Jun 2433035652
31 Mar 24283-4633
31 Dec 23258-28633
30 Sep 23234-23654
30 Jun 23208-40694
31 Mar 23182-48694
31 Dec 22154-66704
30 Sep 22130-70682
30 Jun 22110-73642
31 Mar 2294-78612
31 Dec 2181-72553
30 Sep 2169-74494
30 Jun 2158-74465
31 Mar 2148-75435
31 Dec 2042-76396
30 Sep 2040-67365
30 Jun 2037-61334
31 Mar 2036-54303
31 Dec 1929-48282
30 Sep 1921-56293
30 Jun 1918-59293
31 Mar 1916-61294
31 Dec 1817-66304
30 Sep 1818-61304
30 Jun 1818-61285
31 Mar 1817-55235
31 Dec 1716-44216
30 Sep 1714-35185
30 Jun 1712-24165
31 Mar 1711-21177
31 Dec 1611-20148
30 Sep 1610-20129
30 Jun 169-201210
31 Mar 168-19128
31 Dec 157-18117
30 Sep 156-17117
30 Jun 156-1596
31 Mar 156-1597
31 Dec 146-17910
30 Sep 145-18811
30 Jun 145-17810
31 Mar 144-18712
31 Dec 133-1679

Kaliteli Kazançlar: ADMA has a large one-off loss of $29.0M impacting its last 12 months of financial results to 30th June, 2024.

Büyüyen Kar Marjı: ADMA became profitable in the past.


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: ADMA has become profitable over the past 5 years, growing earnings by 19.1% per year.

Büyüme Hızlandırma: ADMA has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Kazançlar vs. Sektör: ADMA has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).


Özkaynak Getirisi

Yüksek ROE: ADMA's Return on Equity (18.5%) is considered low.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin